What is the appropriate intravenous acyclovir dosing regimen for meningitis in adults, children (≥3 months), and neonates, and how should the dose be adjusted in patients with impaired renal function?

Acyclovir Dosing in Meningitis/Encephalitis

For adults with normal renal function, administer acyclovir 10 mg/kg IV every 8 hours; for children ≥3 months to 12 years, use 500 mg/m² (or 10-20 mg/kg) IV every 8 hours; and for neonates, use 20 mg/kg IV every 8 hours—all for 14-21 days, with mandatory dose reduction based on creatinine clearance in renal impairment. 1, 2, 3

Age-Specific Dosing Regimens

Adults (>12 years)

• Standard dose: 10 mg/kg IV every 8 hours for 14-21 days 1, 3
• Infuse over at least 1 hour to minimize nephrotoxicity risk
• This achieves CSF concentrations approximately 50% of plasma levels 3

Children (3 months to 12 years)

• Recommended dose: 500 mg/m² IV every 8 hours 2
• Alternative weight-based: 10-20 mg/kg IV every 8 hours 2
• Minimum duration: 21 days for this age group due to relapse rates as high as 26-29% with shorter courses 2
• The higher relapse risk in younger children necessitates the longer treatment duration compared to adults

Neonates (Birth to 3 months)

• High-dose regimen: 20 mg/kg IV every 8 hours for 21 days 1, 4
• This higher dose has decreased neonatal mortality to 5% (compared to historical rates of 25-70%) 1
• Approximately 40% of survivors develop normally with this regimen 1
• The pharmacokinetics in neonates show clearance approximately one-third that of adults, but the higher dose is still recommended for efficacy 3

Renal Dose Adjustments

Critical caveat: Acyclovir is primarily renally excreted (62-91% unchanged), making dose adjustment essential in renal impairment 3. The half-life increases dramatically from 2.5 hours (normal function) to 19.5 hours (anuric patients) 3.

Dosing by Creatinine Clearance:

• CrCl >50 mL/min: No adjustment needed—standard dosing
• CrCl 25-50 mL/min: Standard dose every 12 hours
• CrCl 10-25 mL/min: Standard dose every 24 hours
• CrCl <10 mL/min: 50% of standard dose every 24 hours 3

For hemodialysis patients: Administer dose after dialysis session, as acyclovir is dialyzable 3

Treatment Duration and Monitoring

Duration Guidelines:

• Standard minimum: 14-21 days for confirmed HSV encephalitis 1, 2
• Children 3 months-12 years: Minimum 21 days before considering stopping 2
• Consider repeat lumbar puncture at 14-21 days; if CSF PCR remains positive for HSV, continue treatment with weekly CSF PCR until negative 2

Critical Monitoring Requirements:

Renal function monitoring:

• Check serum creatinine at baseline and at least twice weekly during therapy 2
• Nephrotoxicity can occur in up to 20% of patients, typically manifesting after 4 days of therapy 2
• Recent evidence shows toxicity can occur within 48 hours, particularly in frail elderly patients 5
• Maintain adequate hydration throughout treatment to reduce crystalluria risk 2, 6

Hematologic monitoring:

• Check absolute neutrophil count (ANC) at least twice weekly, especially in neonates and young children 4
• Neutropenia (ANC 500-1000/mm³) occurred in 21% of neonates receiving high-dose therapy but resolved without intervention 4
• Consider dose reduction or G-CSF if ANC remains <500/mm³ for prolonged periods 4

Important Clinical Pitfalls

Avoid these common errors:

1. Bolus administration: Never give as rapid IV push—always infuse over ≥1 hour to prevent crystal nephropathy 2, 6, 5

2. Inadequate hydration: Dehydration significantly increases nephrotoxicity risk; ensure adequate fluid intake 2, 6

3. Failure to adjust for renal function: Even mild renal impairment requires dose adjustment given the drug's renal elimination 2, 3

4. Premature discontinuation: The original 10-day regimens showed unacceptable relapse rates; 14-21 days is now standard 2

5. Concomitant nephrotoxins: Exercise caution with other nephrotoxic medications, though recent data suggest this may be less critical than previously thought 7

6. Obesity dosing: Use actual body weight for non-obese patients and adjusted body weight for obese patients to optimize outcomes while minimizing toxicity 8

Special Populations

Elderly patients: Frailty (Clinical Frailty Scale ≥4) is a stronger predictor of acute kidney injury than chronological age or baseline renal function 7. Monitor these patients more intensively regardless of baseline creatinine.

Immunocompromised patients: Consider continuing therapy beyond 21 days if CSF PCR remains positive, with weekly monitoring until clearance 2